The quality of three decision-analytic diabetes models: a systematic health economic assessment

References

• Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5), 1047–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang X, Brown J et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res. Clin. Pract.87(3), 293–301 (2010).
   PubMed Web of Science ®Google Scholar
• Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics26(2), 131–148 (2008).
   PubMed Web of Science ®Google Scholar
• Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ.5(1), 1–11 (1996).
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S; Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Wiley-Blackwell, Chichester, England; NJ, USA (2008).
   Google Scholar
• Centre for Reviews and Dissemination. Systematic Reviews CRD’s Guidance for Undertaking Reviews in Health Care. York Publishing Service Ltd, York, England (2009).
   Google Scholar
• Evers S, Goossens M, De Vet H, Van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on Health Economic Criteria. Int. J. Technol. Assess. Health Care21(2), 240–245 (2005).
   PubMed Web of Science ®Google Scholar
• Tarride J-E, Hopkins R, Blackhouse G et al. A review of methods used in long-term cost–effectiveness models of diabetes mellitus treatment. Pharmacoeconomics28(4), 255–277 (2010).
   PubMed Web of Science ®Google Scholar
• Yi Y, Philips Z, Bergman G, Burslem K. Economic models in Type 2 diabetes. Curr. Med. Res. Opin.26(9), 2105–2118 (2010).
   PubMed Web of Science ®Google Scholar
• The Mount Hood 4 Modelling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting. Diabetes Care30(6), 1638–1646 (2007).
   PubMed Web of Science ®Google Scholar
• Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics24(4), 355–371 (2006).
   PubMed Web of Science ®Google Scholar
• Philips Z, Ginnelly L, Sculpher M et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol. Assess.8(36), iii–iv, ix–xi, 1–158 (2004).
   PubMed Web of Science ®Google Scholar
• Soto J. Health economic evaluations using decision analytic modeling. Principles and practices – utilization of a checklist to their development and appraisal. Int. J. Technol. Assess. Health Care18(1), 94–111 (2002).
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Toy EL, Sandberg EA et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health4(5), 348–361 (2001).
   PubMedGoogle Scholar
• American Diabetes Association. Guidelines for computer modelling of diabetes and its consequences. Diabetes Care27(9), 2262–2265 (2004).
   PubMed Web of Science ®Google Scholar
• CDC Diabetes Cost–Effectiveness Group. Cost–effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for Type 2 diabetes. JAMA287(19), 2542–2551 (2002).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze SP, Lammert M et al. Comparing the long-term cost–effectiveness of repaglinide plus metformin versus nateglinide plus metformin in Type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in Type 2 diabetes. Curr. Med. Res. Opin.20(Suppl. 1), S41–S51 (2004).
   PubMedGoogle Scholar
• Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost–effectiveness of strategies for managing people at high risk for diabetes. Ann. Intern. Med.143(4), 251–264 (2005).
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am. J. Public Health77(11), 1417–1426 (1987).
   PubMed Web of Science ®Google Scholar
• Brändle M, Herman WH. The CORE Diabetes Model. Curr. Med. Res. Opin.20(Suppl. 1), S1–S3 (2004).
   PubMed Web of Science ®Google Scholar
• Palmer A, Roze S, Valentine W et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost–effectiveness of interventions in diabetes mellitus (Types 1 and 2) to support clinical and reimbursement decision-making. Curr. Med. Res. Opin.20(Suppl. 1), S5–S26 (2004).
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr. Med.Res. Opin.20(Suppl. 1), S27–S40 (2004).
   PubMed Web of Science ®Google Scholar
• Eddy DM, Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care26(11), 3093–3101 (2003).
   PubMed Web of Science ®Google Scholar
• Schlessinger L, Eddy DM. Archimedes: a new model for simulating health care systems – the mathematical formulation. J. Biomed. Inform.35(1), 37–50 (2002).
   PubMed Web of Science ®Google Scholar
• Eddy DM, Schlessinger L. Validation of the Archimedes Diabetes Model. Diabetes Care26(11), 3102–3110 (2003).
   PubMed Web of Science ®Google Scholar
• Buxton MJ, Drummond MF, Van Hout BA et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ.6(3), 217–227 (1997).
   PubMed Web of Science ®Google Scholar
• Eddy D. Bringing health economic modeling to the 21st century. Value Health9(3), 168–178 (2006).
   PubMed Web of Science ®Google Scholar
• Schramm W, Schöll M, Trinczek B, Weber C. The prosit disease modelling community – open source development of decision analytic disease models for Type 2 diabetes. ISPOR 10th European Congress Research Abstracts. Value Health10(6), A274 (2007).
   Google Scholar
• Waugh N, Cummins E, Royle P et al. Newer agents for blood glucose control in Type 2 diabetes: systematic review and economic evaluation. Health Technol. Assess.14(36), 1–248 (2010).
   Google Scholar
• Ferdinands JM, Mannino DM. Obstructive lung disease models: what is valid? COPD5(6), 382–393 (2008).
   PubMedGoogle Scholar
• Stearns SC, Drummond M. Grading systems for cost–effectiveness studies: is the whole greater than the sum of the parts? Med. Care41(1), 1–3 (2003).
   PubMedGoogle Scholar